Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets |
| |
| Authors: | Leen Moens Bert Verbinnen Kris Covens Greet Wuyts Marina Johnson Lucy Roalfe David Goldblatt Isabelle Meyts Xavier Bossuyt |
| |
| Affiliation: | aExperimental Laboratory Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium;bLife Sciences, Thomas More Kempen, Geel, Belgium;cCenter for Molecular and Vascular Biology, Department of Cardiovascular Sciences, Faculty of Medicine, KU Leuven, Leuven, Belgium;dImmunobiology Section, Institute of Child Health, University College London, London, United Kingdom;ePediatrics, University Hospitals, Leuven, Belgium |
| |
| Abstract: | The role of CD19+ CD5+ and CD19+ CD5− B cell subpopulations in the antibody response to pneumococcal capsular polysaccharides (caps-PSs) is controversial. In the present study, we evaluated the role of human CD19+ CD5+ and CD19+ CD5− cell populations in the serotype-specific antibody response to caps-PS. After vaccination of 5 healthy human adults with Pneumovax (23-valent pneumococcal polysaccharide vaccine [PPV23]), IgG anti-caps-PS serotype 4 antibody-producing cells resided mainly in the CD19+ CD5− B cell subset, as assessed by enzyme-linked immunosorbent spot (ELISpot) analysis. Moreover, in a humanized SCID mouse model, CD19+ CD5− B cells were more effective than CD19+ CD5+ cells in producing IgG anti-cap-PS antibodies. Finally, an association was found between the level of IgG anti-caps-PS antibodies and the number of CD19+ CD5− B cells in 33 humans vaccinated with PPV23. Taken together, our data suggest that CD5 defines a functionally distinct population of B cells in humans in the anti-caps-PS immune response. |
| |
| Keywords: | |
|
|
